Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
IPO Year: 2018
Exchange: NASDAQ
Website: aquestive.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $7.00 | Outperform | Oppenheimer |
| 12/17/2024 | $17.00 | Overweight | Cantor Fitzgerald |
| 5/10/2024 | $8.00 | Outperform | Leerink Partners |
| 4/11/2024 | $10.00 | Overweight | Piper Sandler |
| 3/28/2024 | $7.00 | Outperform | Raymond James |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
3 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
Fastest customizable press release news feed in the world
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc, Chief Medical Officer of Aquestive Therapeutics (the "Company"), under the Company's 2022 Equity Inducement Plan. The inducement grant was approved by the Company's Compensation Committee. Under the Company's 2022 Equity Inducement Plan, Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units (the "Inducement RSUs") and an equit
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in March as follows: TD Cowen 46th Annual Health Care Conference: Management will be available for 1x1 meetings on Tuesday, March 3rdLeerink Partners Global Healthcare Conference 2026: fireside chat to take place on Monday, March 9th at 10:40am ET; management will also be available for 1x1 meetingsCitizens Life Sciences Confer
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 5, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc
WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, which is a virtual event. The Aquestive team will be presenting on February 26th, at 12 pm ET; management will also be hosting one-on-ones with investors that same day. A webcast of the presentation will be available under the "Events and Presentations" page of the Inve
Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple poster presentations highlighting results from the investigational use of its product candidate Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2026 American
Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi
Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant cashReiterates plans to submit in Canada and EU by the end of 2026Company to host investor call on February 2, 2026, at 8:00am ET WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm NDA application is ongoing and no final FDA decision has been madeProgresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for AnaphylmUnaudited cash and cash equivalents of approximately $120 million as of December 31, 2025 WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sci
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
S-8 - Aquestive Therapeutics, Inc. (0001398733) (Filer)
10-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
S-8 - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
144 - Aquestive Therapeutics, Inc. (0001398733) (Subject)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00
Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00
Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00
Piper Sandler initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $10.00
Raymond James initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00
RBC Capital Mkts resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00
HC Wainwright resumed coverage of Aquestive Therapeutics with a rating of Buy and set a new price target of $14.00
HC Wainwright resumed coverage of Aquestive Therapeutics with a rating of Buy and set a new price target of $14.00
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Live finance-specific insights
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 5, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc
Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant cashReiterates plans to submit in Canada and EU by the end of 2026Company to host investor call on February 2, 2026, at 8:00am ET WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U
Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the third quarter ended September 30, 2
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, November 6, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A liv
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec
WARREN, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2025 and provide an update on recent developments in its business after market close on Monday, August 11, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 12, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast
Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2025, and provided a strategic business update. "In the firs
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, May 13, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the
Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectationsAQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 millionCompany to host investment community conference call on March 6, 2025 WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medi
This live feed shows all institutional transactions in real time.
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
Live Leadership Updates
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr
Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N
Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October
Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo
Daniel Barber, current Chief Operating Officer of Aquestive, appointed as President and Chief Executive Officer and member of Board of DirectorsKeith Kendall, President and Chief Executive Officer and member of Board of Directors, will be leaving the CompanyKeith Kendall engaged as consultant to end of year to assist in management transition WARREN, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that Keith Kendall, President and Chief Executive Officer and member of the
WARREN, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced that A. Ernest (Ernie) Toth, Jr., a seasoned financial executive and currently serving the Company as the interim Chief Financial Officer, has transitioned to the permanent role of Senior Vice President and Chief Financial Officer effective immediately. "Ernie is a seasoned and experienced financial executive. He has become a valued member of our team and an important part of our external relationships in the financial comm
MANCHESTER, England & DETROIT--(BUSINESS WIRE)--Wejo, the leader in connected vehicle data, today announced that Chief Financial Officer Barry Nightingale is planning to retire and John Maxwell has been appointed his successor in the role. The changes to the leadership team are effective immediately and come at a time of significant growth for the company, which enables mobility intelligence by 12 billion data points a day from 10.6 million vehicles out of a supply base of 50 million vehicles. During his tenure at Wejo, Nightingale helped lead the company from early-stage tech startup to global connected vehicle data leader. This included the $42 million of recent funding to ensu